The Annals Summaries of the Latest Medical Research!
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 36, No. 7, pp. 1150-1155. DOI 10.1345/aph.1A328
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ng, E
Right arrow Articles by Taddio, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, E
Right arrow Articles by Taddio, A


Research Articles

Safety of benzodiazepines in newborns

E Ng, G Klinger, V Shah, and A Taddio

BACKGROUND: Benzodiazepines are being used in neonatal intensive care units for sedation and control of seizures. However, anecdotal reports suggest that their use in infants may be associated with serious adverse effects (AEs). OBJECTIVE: To determine the incidence of AEs from benzodiazepine use in preterm and full-term infants. METHODS: Retrospective chart review of 63 infants who received benzodiazepines as a sedative or anticonvulsant over a 16-month period. RESULTS: Mean +/- SD gestational age of the infants was 33.1 +/- 6.2 weeks, and birth weight was 2.3 +/- 1.2 kg. Median (range) postnatal age at commencement of drug administration was 19 (5-54) days. Forty-one infants received lorazepam, 8 received midazolam, and 14 received both. Ten (16%) of the infants had 14 documented adverse events: seizures (n = 6), hypotension (n = 5), and respiratory depression (n = 3). Using a validated adverse drug reaction probability scale, a probable association with benzodiazepine use was demonstrated in 12 of the AEs. Due to the retrospective nature of the data, a score for definite association was not attainable. Anticonvulsant administration was required for 4 of 6 infants and, in all cases of respiratory depression, ventilatory support was initiated or increased. Two cases of significant hypotension were treated with inotropes. There was no statistically significant correlation between AEs and benzodiazepine dose or concomitant use of inotropes or analgesics (morphine), although most infants had underlying medical conditions or received multiple drugs that may have predisposed them to experience AEs. CONCLUSIONS: Administration of benzodiazepines was frequently associated with AEs in full-term and preterm infants. It is possible that underlying illnesses and concomitant drug use predisposed these effects. Until the benefit-to-risk ratio is determined by further studies, judicious use of benzodiazepines is recommended in this vulnerable population.


This article has been cited by other articles:


Home page
J Child NeurolHome page
D. Sirsi, S. Nangia, J. LaMothe, B. E. Kosofsky, and G. E. Solomon
Successful Management of Refractory Neonatal Seizures With Midazolam
J Child Neurol, June 1, 2008; 23(6): 706 - 709.
[Abstract] [PDF]


Home page
J Clin PharmacolHome page
A. Zuppa, S. Vijayakumar, B. Jayaraman, D. Patel, M. Narayan, K. Vijayakumar, J. T. Mondick, and J. S. Barrett
An Informatics Approach to Assess Pediatric Pharmacotherapy: Design and Implementation of a Hospital Drug Utilization System
J. Clin. Pharmacol., September 1, 2007; 47(9): 1172 - 1180.
[Abstract] [Full Text] [PDF]


Home page
NeoReviewsHome page
J. J. Riviello Jr
Pharmacology Review: Drug Therapy for Neonatal Seizures: Part 1
NeoReviews, May 1, 2004; 5(5): e215 - e220.
[Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.